Tempest Therapeutics, Inc. filed a Form 8-K on October 30, 2026, reporting the resignation of Chief Financial Officer Constance Ames and the immediate appointment of Stephanie Horn-Warnock as CFO, effective October 26, 2026.

Key Highlights

  • CFO departure: Constance Ames resigned as Chief Financial Officer effective October 26, 2026, citing personal considerations unrelated to the company, according to the filing.
  • New CFO appointed: The Board of Directors appointed Stephanie Horn-Warnock as Chief Financial Officer, Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary, also effective October 26, 2026.
  • Compensation structure: Horn-Warnock will serve as a consultant at a rate of $450 per hour, plus expenses and an indirect cost allocation of 5.0% of total professional fees.
  • Consulting engagement: The engagement letter governing Horn-Warnock's services is dated October 28, 2026.
  • Experience: Horn-Warnock, age 37, has more than 14 years of experience in accounting, financial reporting, auditing, and financial management, according to the filing.
  • No related-party issues: The filing states there are no family relationships between Horn-Warnock and any directors or executive officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.

CFO Transition at Tempest Therapeutics: Ames Out, Horn-Warnock In

According to the Form 8-K filed with the SEC on October 30, 2026, Constance Ames informed Tempest Therapeutics, Inc. on October 26, 2026, that she was resigning from her role as Chief Financial Officer and from all other positions she held with the company. The filing states the resignation was "for personal considerations unrelated to the Company" and was effective immediately.

On the same date, the company's Board of Directors appointed Stephanie Horn-Warnock, 37, to fill the CFO role, along with the titles of Principal Financial and Accounting Officer, Treasurer, and Corporate Secretary. The filing notes that Horn-Warnock will provide services as a consultant under an engagement letter dated October 28, 2026, at a rate of $450 per hour, plus expenses and an indirect cost allocation of 5.0% of total professional fees. She will also enter into the company's standard form of indemnification agreement.

The filing describes Horn-Warnock's background as spanning more than 14 years across healthcare, pharmaceutical, medical technology, behavioral health, and renewable energy industries. Most recently, from January 2024 to September 2026, she served as Vice President of Finance at ROM Technologies Inc. Since March 2026, she has also worked through Stout Risius Ross, LLC in financial leadership and consulting roles, including as Controller of Diasome Pharmaceuticals, Inc. and Assistant Controller of Aspargo Labs, Inc. She holds a B.B.A. in Accounting from Emory University's Goizueta Business School and is a Certified Public Accountant. The company's common stock is listed on NASDAQ:TPST.

What Was Disclosed

Tempest Therapeutics disclosed the resignation of CFO Constance Ames and the immediate appointment of Stephanie Horn-Warnock as CFO and related officer roles, including the consulting fee structure of $450 per hour plus a 5.0% indirect cost allocation.